Genomic Classifier in Prostate Cancer: Intermediate-Risk

Epidemiology Applied to Focal Therapy in Prostate Cancer: Where do we Stand? - Kae Jack Tay

May 15, 2024

Details

The Future of Prostate Cancer Risk Stratification and Treatment Planning - Eric Kim

May 10, 2024

Details

The Future of Prostate Cancer Diagnosis: Combining Non-Invasive Tests for Personalized Care - Eric Kim

May 10, 2024

Details

Investigating the Relationship Between MRI Findings, Genomic Markers, and Gleason Score - Eric Kim

May 10, 2024

Details

Precision Risk Assessment in Prostate Cancer: Growing Utility in NCCN Guidelines - Rashid Sayyid & Zachary Klaassen

April 3, 2024

Details

A Comprehensive Look at Genomic Classifier Performance in Intermediate Risk Prostate Cancer: Insights from the NRG Oncology/RTOG 01-26 Trial, Journal Club - Rashid Sayyid & Zachary Klaassen

August 22, 2023

Details

Risk Assessment in Localized Prostate Cancer - Insights from Real-World Data and SEER Registry - Jim Hu

May 9, 2023

Details

The Use of Genomics in Unfavorable Intermediate-risk Prostate Cancer - David Morris

December 20, 2022

Details

The Molecular Biology of Prostate Cancer - Christopher Barbieri

October 28, 2022

Details

Treatment of Unfavorable Intermediate Risk Prostate Cancer - Ashley Ross, Jason Hafron, and Katie Murray

June 14, 2022

Details

The Benefit of ADT Treatment Intensification With Radiotherapy in Localized Prostate Cancer – Dan Spratt and Amar Kishan

May 24, 2022

Details

Validation of Performance of the Decipher® Biopsy Genomic Classifier in Intermediate-Risk Prostate Cancer: The Phase III Randomized Trial NRG Oncology/RTOG 0126 – Jeff Michalski

February 24, 2022

Details

The Impact of Decipher® Biopsy Testing on Clinical Outcomes in Localized Prostate Cancer – Randy A. Vince Jr.

January 23, 2022

Details

A Systematic Review of the Decipher® Genomic Classifier in Prostate Cancer - Ashley Ross & Daniel Spratt

February 16, 2021

Details